Investors Affected by RxSight, Inc. Securities Fraud Urged to Act Before September 22 Deadlines

Urgent Call for Action: RxSight, Inc. Investors

Shareholders of RxSight, Inc. (NASDAQ: RXST), who have faced financial losses, are advised to take immediate action due to a securities class action lawsuit recently filed by Wolf Haldenstein Adler Freeman & Herz LLP. This lawsuit aims to represent all individuals or entities that purchased RxSight's securities during a specified period. The lead plaintiff deadline looms ahead on September 22, 2025, making it imperative for affected investors to reach out without delay.

Understanding the Allegations

The lawsuit centers around claims of securities fraud and other unlawful business practices attributed to RxSight, as well as its officers and directors. Investors who acquired RxSight securities between November 7, 2024, and July 8, 2025, may qualify to join the class action. The timing of the lawsuit coincides with troubling disclosures made by RxSight that signaled trouble for the company and its shareholders.

On July 8, 2025, RxSight made a significant announcement detailing its preliminary financial results for the second quarter of 2025. The company revealed a stark decline in sales of its Light Delivery Device (LDD) and a reduction in the usage of its adjustable intraocular lenses. This news was particularly concerning, coupled with an overall revenue shortfall leading to a slashing of the full-year guidance by approximately $42.5 million.

CEO Ronald Kurtz explicitly stated that the downturn in sales was largely due to